IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

Reliable pre-eclampsia pathways based on multiple independent microarray data sets

(2014) Kaoru Kawasaki et al.   MOLECULAR HUMAN REPRODUCTION

PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

(2013) K. Abiko et al.   CLINICAL CANCER RESEARCH

Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis

(2013) Joji Kitayama et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Latest research and treatment of advanced-stage epithelial ovarian cancer

(2013) Robert L. Coleman et al.   Nature Reviews Clinical Oncology

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-Derived Suppressor Cells Modulate Immune Responses Independently of NADPH Oxidase in the Ovarian Tumor Microenvironment in Mice

(2013) Heidi E. Godoy et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature

(2012) Qiong-wen Zhang et al.   PLoS One

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The Two Faces of Interferon-  in Cancer

(2011) M. R. Zaidi et al.   CLINICAL CANCER RESEARCH

The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors

(2011) Junzo Hamanishi et al.   CLINICAL IMMUNOLOGY

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

(2011) Wei-Ting Hwang et al.   GYNECOLOGIC ONCOLOGY

The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer

(2011) Shogo Yamamura et al.   INTERNATIONAL JOURNAL OF CANCER

Immune Therapy for Ovarian Cancer: Promise and Pitfalls

(2011) Suzanne R. Thibodeaux et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype

(2009) Jason C. Barnett et al.   GYNECOLOGIC ONCOLOGY

The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade

(2009) Lana E. Kandalaft et al.   GYNECOLOGIC ONCOLOGY

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis

(2008) Kui Li et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

(2008) David S. Alberts et al.   GYNECOLOGIC ONCOLOGY

Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression

(2008) Min Liu et al.   MODERN PATHOLOGY